- Home
- CANF vs KXIN Comparison
CANF vs KXIN Comparison
Compare CANF & KXIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CANF | KXIN |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | Israel | China |
| Employees | N/A | 13 |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 7.0M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | CANF | KXIN |
|---|---|---|
| Price | $3.27 | $4.30 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $50.00 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 49.2K |
| Earning Date | 03-26-2026 | 11-26-2019 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,715,455.50 | N/A |
| Revenue Next Year | $101.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.11 |
| 52 Week High | $10.40 | $22.00 |
Technical Indicators
Market Signals| Indicator | CANF | KXIN |
|---|---|---|
| Relative Strength Index (RSI) | 50.45 | 39.30 |
| Support Level | $2.88 | $4.05 |
| Resistance Level | $3.42 | $5.86 |
| Average True Range (ATR) | 0.51 | 0.34 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 21.64 | 34.44 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto dealership company mainly engaged in the sale of domestic and imported automobiles in China. The company provides new and used car buyers in China with access to a wide selection of used vehicles across its network of dealerships, with a focus on premium brands such as Audi, BMW, Mercedes-Benz, Land Rover, and Porsche. The company generates revenue from automobile sales and related services.